Advertisement
Advertisement

Iopromide


Generic Medicine Info
Indications and Dosage
Intra-arterial
Aortography, Visceral angiography
Adult: As 370 mg iodine/mL: Individualise volume and rate of administration proportioned to the blood flow and specific characteristics of vessels being examined. Max total dose: 225 mL. Administer at a rate approximately equal to the flow rate of the vessel being injected. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intra-arterial
Coronary arteriography, Left ventriculography
Adult: As 370 mg iodine/mL: Left or right coronary artery: 3-14 mL. Left ventricle: 30-60 mL. Max total dose: 225 mL. Administer at a rate approximately equal to the flow rate of the vessel being injected. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intra-arterial
Radiographic evaluation of cardiac chambers and related arteries
Child: >2 years As 370 mg iodine/mL: 1-2 mL/kg. Max total dose: 4 mL/kg. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intra-arterial
Peripheral arteriography
Adult: As 300 mg iodine/mL: Subclavian or femoral artery: 5-40 mL. Aortic bifurcation (distal runoff): 25-50 mL. Max total dose: 250 mL. Administer at a rate approximately equal to the flow rate of the vessel being injected. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intra-arterial
Cerebral arteriography
Adult: As 300 mg iodine/mL: Carotid artery visualisation: 3-12 mL. Vertebral artery visualisation: 4-12 mL. Aortic arch inj: 20-50 mL. Max total dose: 150 mL. Administer at a rate approximately equal to the flow rate of the vessel being injected. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intravenous
Contrast-enhanced computerised tomography
Adult: As 300 mg iodine/mL: Head: 50-200 mL via IV inj (Max total dose: 200 mL). Body (intra-abdominal, intrathoracic, and retroperitoneal regions): As single phase contrast: 50-200 mL via IV bolus inj or 100-200 mL via rapid infusion (Max total dose: 200 mL). As multiple phase contrast: 50-200 mL total volume via IV inj (Max total dose: 200 mL). As 370 mg iodine/mL: Head: 41-162 mL via IV inj (Max total dose: 162 mL). Body (intra-abdominal, intrathoracic, and retroperitoneal regions): As single phase contrast: 41-162 mL via bolus inj or 81-162 mL via rapid infusion (Max total dose: 162 mL). As multiple phase contrast: 41-162 mL total volume via IV inj (Max total dose: 162 mL). For multiple phase contrast, administer 100% contrast in phase 1 and 20-60% contrast in phase 2, using a power injector suitable for the simultaneous administration of contrast and 0.9% NaCl inj. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).
Child: >2 years As 300 mg iodine/mL: 1-2 mL/kg. Max total dose: 3 mL/kg. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intravenous
Excretory urography
Adult: As 300 mg iodine/mL: 1 mL/kg. Max total dose: 100 mL. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).
Child: >2 years As 300 mg iodine/mL: 1-2 mL/kg. Max total dose: 3 mL/kg. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).

Intravenous
Contrast enhanced mammography
Adult: As 300 or 370 mg iodine/mL: 1.5 mL/kg using a power injector at 2-4 mL/second. Max total dose: 150 mL. Recommendations may vary among countries and between individual products (refer to specific product or local guidelines).
What are the brands available for Iopromide in Malaysia?
  • Ultravist
Renal Impairment
Use the lowest required dose.
Special Precautions
Patient with heart failure; severe arterial or venous disease; history of hypersensitivity reactions to contrast agents, known allergies (e.g. bronchial asthma, food or medication allergies); risk factors for nephrotoxicity (e.g. advanced vascular disease, CHF, dehydration, diabetes mellitus); known or suspected phaeochromocytoma, hyperthyroidism or goitre; multiple myeloma, myasthenia gravis; sickle cell disease. Avoid extravasation and use in patients with a history of contrast-induced serious rash. Not approved for intrathecal administration. Children. Pregnancy and lactation. Renal and hepatic impairment.
Adverse Reactions
Significant: Severe cutaneous reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms); extravasation resulting in tissue necrosis or compartment syndrome; acute renal injury, including renal failure; thyroid storm; exacerbation of myasthenia gravis; hypertensive crisis (particularly in patients with phaeochromocytoma); sickling (particularly in patients homozygous for sickle cell disease).
Cardiac disorders: Chest pain or discomfort, arrhythmia.
Eye disorders: Blurred or disturbed vision.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Injection site reactions (e.g. rash, erythema, pain, swelling, bleeding, haematoma).
Nervous system disorders: Dizziness, headache, dysgeusia, vasovagal reactions, confusional state, restlessness, paraesthesia, hypoaesthesia, somnolence.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.
Vascular disorders: Hypertension, hypotension, vasodilatation.
Potentially Fatal: Hypersensitivity reactions, including anaphylaxis. Rarely, CV reactions (e.g. hypotension, shock, cardiac arrest), thromboembolic events (e.g. MI, stroke).
Patient Counseling Information
Ensure adequate fluid intake before and after the procedure.
Monitoring Parameters
Obtain hypersensitivity or allergy history before administration. Monitor renal function, blood pressure, hydration, and the infusion site for extravasation during IV administration. Assess for signs of hypersensitivity reactions and CV events.
Overdosage
Symptoms: Fluid and electrolyte imbalance, renal failure, CV and pulmonary complications. Management: Symptomatic and supportive treatment. Monitor fluids, electrolytes, and renal function.
Drug Interactions
May increase the risk of metformin-induced lactic acidosis. Increased risk of delayed reactions when previously treated with interleukin-2. May reduce the diagnostic and therapeutic efficacy of radioactive iodine (e.g. I-131 and I-123).
Lab Interference
May result in inaccurate protein-bound iodine tests for up to 16 days after administration.
Action
Description:
Mechanism of Action: Iopromide is a nonionic, monomeric, iodinated radiographic contrast agent. It opacifies vessels where the contrast medium is present, which permits radiographic visualisation of internal structures.
Pharmacokinetics:
Distribution: Rapidly distributed in the extracellular fluid. Crosses the placenta. Plasma protein binding: 1%.
Metabolism: Not metabolised.
Excretion: Via urine (97% as unchanged drug); faeces (2%). Elimination half-life: 2 hours (main phase); 6.2 hours (terminal phase).
Chemical Structure

Chemical Structure Image
Iopromide

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3736, Iopromide. https://pubchem.ncbi.nlm.nih.gov/compound/Iopromide. Accessed June 26, 2025.

Storage
Store between 15-30°C. Protect from light and ionising radiation.
MIMS Class
Radiographic & Diagnostic Agents
ATC Classification
V08AB05 - iopromide ; Belongs to the class of watersoluble, nephrotropic, low osmolar preparations used as X-ray contrast media.
References
Brayfield A, Cadart C (eds). Iopromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/05/2025.

Iopromide. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 05/05/2025.

Iopromide. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/05/2025.

Ultravist 300/370, Solution for Injection/Infusion (Bayer Co. [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 05/05/2025.

Ultravist Injection (Bayer Healthcare Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 14/05/2025.

Disclaimer: This information is independently developed by MIMS based on Iopromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement